Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. develops clinical-stage neuroplastogen-derived therapeutics focused on mental health and substance-use disorders. News for CMND centers on CMND-100, the company's proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder, including clinical-trial safety, tolerability, pharmacokinetic and preliminary efficacy updates from a multinational Phase I/IIa study.
Company updates also cover intellectual-property activity for psychedelic and neuroplastogen compounds, including patent applications and licensed development rights tied to PTSD and other mental health disorders. Additional recurring themes include FDA-related clinical communications, data-safety monitoring reviews, clinical-site progress and scientific presentations around MEAI.
Clearmind Medicine Inc. (Nasdaq: CMND) has submitted a new patent application to the USPTO for a novel composition combining its MEAI compound with SciSparc's PEA to treat metabolic syndrome and obesity. This application is part of ongoing collaborations with SciSparc (Nasdaq: SPRC) and Prof. Joseph Tam from the Hebrew University.
The obesity treatment market, valued at $15 billion in 2022, is expected to grow at a CAGR of 10.0% from 2023 to 2032. This growth is driven by the increasing prevalence of obesity, with the CDC reporting a 41.9% obesity rate among US adults aged 20 and over.
Clearmind has filed a total of twelve patent applications with the USPTO for various proprietary compositions, including treatments for alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders.
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech firm, will present significant research at the Psychedelic Medicine – Israel 2024 conference in Tel Aviv from July 28-30. CEO Adi Zullof-Shani, Ph.D., will discuss the potential of 5-Methoxy-2-Aminoindane (MEAI) as a regulator of binge behaviors on July 29. Additionally, researchers Prof. Joseph Tam and Dr. Saja Baraghithy will present a study on MEAI's effects on diet-induced obesity on July 30. Their findings indicate MEAI's promise in reducing obesity and improving metabolic health. The conference aims to advance psychedelic medicine through international collaboration and research dissemination.
Clearmind Medicine, focused on developing psychedelic-derived therapeutics, announced patent approval for its MEAI-based binge behavior regulator in Hong Kong. The newly granted patent enhances Clearmind's intellectual property portfolio, which now includes 28 patents across 18 patent families in key regions like the US, Europe, China, India, and Hong Kong. The company's innovative molecule, MEAI, reduces the desire to consume alcohol and provides a mild euphoria similar to alcohol. This treatment is particularly aimed at managing Alcohol Use Disorder and binge drinking, offering potential benefits to millions who struggle with alcohol moderation.
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech firm, has secured an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This deal grants Clearmind global rights to develop, manufacture, and commercialize novel psychedelic-derived compounds aimed at treating PTSD and other mental health conditions. The potential PTSD treatment market is estimated to grow from $16.8 billion in 2023 to $27.37 billion by 2033. Current treatments for PTSD, such as SSRIs and SNRIs, often show efficacy and side effects like nausea and insomnia. Clearmind's agreement includes milestone payments, royalties, and IP protection commitments.
Clearmind Medicine (Nasdaq: CMND) announced advancements in its MEAI-based alcohol substitute beverage program, targeting the $13 billion non-alcoholic beverages market. The company completed the last pre-clinical study needed for a novel-food application. This project, led by Nicholas Kadysh, an expert with former roles at Red Bull Canada and Juul Labs Canada, has received patents in the U.S., India, and Europe. According to IWSR, the no/low alcohol market, valued at $13 billion in 2023, is expected to grow at a CAGR of 6% through 2027. Clearmind aims to develop psychedelic-derived therapeutics for under-treated health problems, boasting a portfolio of 18 patent families and 27 granted patents.
Clearmind Medicine Inc. announces progress in its proprietary MEAI-based alcohol substitute beverage program, aiming to introduce a health-focused alternative to traditional alcoholic drinks. The company has completed pre-clinical studies for a novel-food application submission and obtained patents in the U.S., India, and Europe. Led by industry experts, the project aligns with the global trend towards no- and low-alcohol consumption in a market estimated to be over $13 billion by 2023.
Clearmind Medicine Inc. (Nasdaq: CMND) secures global rights to innovative psychedelic compounds for PTSD treatment through an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. The global market for PTSD treatment is projected to reach $27.37 billion by 2033. Clearmind aims to revolutionize mental health care with these novel compounds, offering hope to millions worldwide.
Clearmind Medicine Inc. has applied to cease being a reporting issuer in Canada by seeking an order from the Canadian Securities Regulators. If approved, the company will no longer be required to file financial statements and other continuous disclosure documents in Canadian jurisdictions. However, Clearmind will continue to comply with U.S. and German laws and regulations, as well as Nasdaq and FSE rules. Shareholders can access all disclosure documents on the company's website, and Canadian shareholders will receive necessary documents in line with U.S. and German requirements.
Summary not available.
Summary not available.